Health & Fitness
Health and Fitness
Health and Fitness 
Wed, April 13, 2011
XenoPort Announces Presentation of Preclinical Data for Novel Fumarate Analog XP23829 at the 63rd Annual Meeting of the America
SANTA CLARA, Calif.--([ BUSINESS WIRE ])--XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on a preclinical product candidate, XP23829, at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii. The poster, which is entitled aComparison of the Efficacy and Tolerability of a Novel Methyl Hydrogenfumarate (MHF) Prodrug with Dimethylfumarate (DMF) in Rodent EAE and GI Irritation Models,a will be presented at Poster Session V, Wednesday, April 13, from 2:00 p.m. to 6:30 p.m. Hawaii-Aleutian Standard Time.
"Comparison of the Efficacy and Tolerability of a Novel Methyl Hydrogenfumarate (MHF) Prodrug with Dimethylfumarate (DMF) in Rodent EAE and GI Irritation Models"
About XP23829
XP23829 is a new chemical entity that is a prodrug of MHF, a molecule that appears to have anti-inflammatory properties and the potential to modulate cellular responses to oxidative stress. An oral formulation of fumaric acid esters (mixed DMF and monoethylfumarate salts) is approved in Germany and widely used for the treatment of psoriasis. BG-12, an oral formulation of DMF (a prodrug of MHF) from Biogen Idec Inc. has shown promise in late-stage clinical trials for the potential treatment of relapsing-remitting multiple sclerosis (MS).
In preclinical studies that compared molar equivalent doses of XP23829 to DMF, XP23829 provided higher blood levels of the biologically active molecule MHF, superior efficacy in an animal model of MS and fewer and less severe stomach lesions in an animal model of gastric irritation.
XenoPort has filed patent applications on the composition of matter and methods of use of XP23829 and related compounds and owns all rights to the compound.
About XenoPort
XenoPort is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. In April 2011, the U.S. Food and Drug Administration approved XenoPorta™s first product, known in the United States as Horizanta" (gabapentin enacarbil) Extended Release Tablets. GlaxoSmithKline holds commercialization rights and certain development rights for gabapentin enacarbil in the United States. Gabapentin enacarbil is also being developed in partnership with Astellas Pharma Inc. for the potential treatment of Restless Legs Syndrome in Japan. XenoPort's pipeline of product candidates includes potential treatments for patients with neuropathic pain, spasticity and Parkinson's disease. Except for gabapentin enacarbil, XenoPort owns rights to all of its product candidates.
To learn more about XenoPort, please visit the Website at [ www.XenoPort.com ].
Forward-Looking Statements
This press release contains "forward-looking" statements, including, without limitation, all statements related to the therapeutic potential of MHF, believed to be the active agent of XP23829, and the therapeutic potential of XP23829. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "appears," "potential," "promise," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks inherent in preclinical and clinical development; the availability of resources to develop XenoPort's preclinical product candidates; and the uncertain therapeutic and commercial value of XenoPort's preclinical product candidates. These and other risk factors are discussed under the heading "Risk Factors " in XenoPort' s Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission on March 1, 2011. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
XenoPort is a registered trademark of XenoPort, Inc.
Source code: XNPT2C